https://www.selleckchem.com/pr....oducts/brigatinib-ap
s in this largely unexplored territory. TRIAL REGISTRATION This study has been registered 30th October 2018 at clinicaltrials.gov as NCT03724994.BACKGOUND Intravitreal injections are the most common treatment modality for several retinal pathologies. Despite endophthalmitis being the most feared complication, antibioprophylaxis remains controversial in intravitreal injections. METHODS This was a retrospective study done for a period of 2 years from 1st January 2017 to 31st December 2018 in B. P Koirala Lions Centre for Ophtha
Like
Comment
Share
